OIG Remains Focused On Pharmaceutical Copayment Coupons

Law360, New York ( October 22, 2014, 12:38 PM EDT) -- On Sept. 19, 2014, the U.S. Department of Health and Human Services' Office of Inspector General simultaneously issued a report and special advisory bulletin addressing the use of copayment coupons by pharmaceutical manufacturers to reduce or eliminate immediate out-of-pocket costs for specific prescription drugs. These releases indicate that pharmaceutical manufacturers and pharmacies may have legal exposure if copayment coupon programs are not carefully implemented and monitored to ensure the coupons are not used by patients for prescriptions covered under federal health care programs....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!